SCN2A: Biological Roles and Therapeutics Strategies 

• Gene Information: Human SCN2A, located on chromosome 2, encodes the pore-forming α-subunit of voltage-gated sodium channel NaV1.2, a core neuronal ion channel. The NaV1.2 protein comprises four homologous domains, and each domain contains six transmembrane segments. 
• Protein Expression: NaV1.2 is predominantly expressed throughout the central nervous system, with the highest abundance in excitatory neurons. 
• Signaling Pathway: NaV1.2 mediates rapid Na+ influx across the neuronal membrane. This process initiates and propagates neuronal action potentials, thereby governing synaptic transmission and neural circuit excitability. 
• Therapeutic Inhibition: SCN2A serves as a critical therapeutic target for multiple neurodevelopmental disorders with opposite pathological mechanisms: For gain-of-function (GoF) variants causing early-onset developmental and epileptic encephalopathy (DEE): Sodium channel blockers and SCN2A expression suppressors exert prominent therapeutic benefits to alleviate recurrent seizures; For loss-of-function (LoF) variants associated with autism spectrum disorder (ASD): Upregulating NaV1.2 expression or activating channel function is the rational therapeutic direction.

SCN2A 

• The exons 1-27 of mouse Scn2a gene that encode the whole molecule (ATG to STOP codon), including 3’UTR were replaced by human counterparts in B-hSCN2A mice. 
• The promoter and 5’UTR region of the mouse gene are also replaced. The mouse Scn2a gene transcription and translation will be disrupted.

• Human SCN2A mRNA was detectable only in heterozygous B-hSCN2A mice but not in wild-type mice.

Strain specific analysis of SCN2A mRNA expression in wild-type C57BL/6JNifdc mice and heterozygous B-hSCN2A mice by RT-PCR. Cortex RNA were isolated from wild-type C57BL/6JNifdc mice (+/+) and heterozygous B-hSCN2A mice (H/+), then cDNA libraries were synthesized by reverse transcription, followed by PCR with mouse or human SCN2A primers. Mouse Scn2a mRNA was detectable in wild-type mice and heterozygous B-hSCN2A mice. Human SCN2A mRNA was detectable only in heterozygous B-hSCN2A mice but not in wild-type mice, and human sequences were confirmed via Sanger sequencing.

• Human SCN2A protein was detectable in homozygous B-hSCN2A mice and wild-type C57BL/6JNifdc mice. This antibody cross-recognized both human and mouse SCN2A protein.

Western blot analysis of SCN2A protein expression in homozygous B-hSCN2A mice. Various tissue lysates were collected from wild-type C57BL/6JNifdc mice (+/+) andhomozygous B-hSCN2A mice (H/H), and then analyzed by western blot with anti-SCN2A antibody (Abcam, ab300112). 40 μg total proteins were loaded for western blotanalysis. SCN2A protein was detectable in homozygous B-hSCN2A mice and wild-type C57BL/6JNifdc mice. This antibody cross-recognized both human and mouse SCN2Aprotein.
Note: Repeat Western blot experiments are in progress for further validation using another antibody.

The human SCN2A levels in the treatment group were reduced compared to the control group, demonstrating that B-hSCN2A mice provide a powerful preclinical model for in vivo evaluation of human SCN2A-targeted nucleic acid drugs. 

The inhibitory efficiency of the SCN2A-targeted small nucleic acid drug in heterozygous B-hSCN2A mice. B-hSCN2A mice were randomly divided into 2 groups (n=3/5, 8-week-old, male). The human SCN2A-targeted nucleic acid drug (Elsunersen analog, ASO) and artificial cerebrospinal fluid (αCSF) were administered to the miceindividually. The mice were sacrificed on day 14, and the brains (mid-brain, cortex, hippocampus and cerebellum) were collected to detect the human SCN2A expressionby RT-qPCR. (A) The schematic diagram of experimental processing. (B) The expression of human SCN2A mRNA in cortex, hippocampus, mid-brain and cerebellum. Gapdh served as an internal reference gene, and SCN2A expression in each tissues was normalized to that in control group. The human SCN2A mRNA in the treatment group was significantly reduced compared to the control group. Values are expressed as mean ± SEM. Significance was determined by 2-way ANOVA. *P < 0.05, **P <0.01, ***P < 0.001.